CTBE Initiates Randomized Controlled Cohort in Corporate Clinical Trial for Knee Anterior Cruciate Ligament Reconstruction Treatment
NQ Score
83/100
N1 Content Completeness
85
AI Summary (NQ-processed)
CoreTissue BioEngineering (CTBE) has announced the completion of the safety evaluation cohort and the initiation of a randomized controlled cohort for its corporate clinical trial targeting knee anterior cruciate ligament (ACL) reconstruction with its medical device under development, "Tissue Regenerative Ligament" (development code: CT-ACL001). This trial will be conducted at six facilities nationwide, comparing the safety and efficacy against the standard treatment of ACL reconstruction using the patient's own hamstring tendon.